The statement from our government’s health leaders that Tylenol causes autism is not backed by science. In fact, every major medical organization has stated that acetaminophen remains the safest pain and fever option in pregnancy when used as directed.
Tablets can appear to be the most economical dosage form for investigational medicines, and it is natural to want to contain costs as much as possible in the early stages of development. However, softgels offer significant long-term advantages that can lead to a better return on investment for drug sponsors. The primary long-term benefits include improved bioavailability, enhanced patient compliance, and superior product stability.
This commentary highlights how the advances in technology, risk assessment, and regulatory guidelines have excluded human intervention in aseptic filling, improving both product quality and patient safety.
The risk of microbiological contamination during aseptic processing during the past four decades is largely a reflection of technological advances, the application of microbiological risk management tools, and the emphasis on contamination control by regulators.
The purpose of this column is to highlight
and summarize recent key patents in the
The pharmaceutical arena issued by the US
Patent Office in June and July, 2025.
“Traditional” methods are viewed as the gold standard, highly recognized, widely regulated, and backed by decades of acceptance, which leaves little external pressure to move away from them. On the other hand, adopting rapid methods requires significant investment in new technologies, extensive validation to meet regulatory expectations, and overcoming cultural hesitation to abandon a well-established approach.
The healthcare sector is undergoing a profound transformation as at-home injectable treatments become increasingly prevalent.
Rare diseases (i.e., “orphan diseases”) represent a global health challenge that affects around 500 million people worldwide. Most rare disease sufferers face lifelong hurdles in diagnosis and obtaining effective medications. Despite the rapid pace of medical innovation, fewer than 6% of rare diseases have approved therapies, leaving many patients with few solutions and even less hope.
Harnessing the full potential of data in pharmaceutical manufacturing can be complex for life sciences companies. Challenges include connecting systems, comparing data from sites with different systems, managing the volume, variety, and quality of information, overcoming data silos, and legacy technology. These all exacerbate interoperability, contextualization, and statistics issues, which impede innovation.
Many commonly used excipients were developed decades ago and may not be optimal for formulating today’s increasingly complex molecules into effective therapeutics. This is especially true for the growing number of poorly soluble and poorly bioavailable BCS Class II and IV active pharmaceutical ingredients (APIs) in the development pipeline.
The therapeutic promise of RNA-based medicines has never been more visible. From pandemic-era vaccines to next-generation cancer treatments, RNA is fast becoming a leading modality for precision medicine. Among its most exciting applications are personalized cancer therapeutics - custom-designed mRNA therapies tailored to a specific patient’s tumor profile. But as the PCT field matures, new bottlenecks are emerging in the areas of delivery and manufacturing, hindering widespread usage.
We will see more robust automation technologies on the market to address the evolving expectations for QC microbiology. As regulations become more prescriptive, leaving less room for interpretation, and as manufacturing throughput becomes more crucial for newly marketed drugs, the expectation will be that automation can support these drivers rather than sometimes being the bottleneck to getting product to market.
Pharma companies want fewer surprises and faster answers. We see more continuous monitoring instead of spot checks, systems built for data integrity from the start, and cloud tools that make compliance easier to scale across sites. The big shift: clients want monitoring to feel less like paperwork and more like a live dashboard they can trust.
At the peak of the COVID-19 pandemic, the role of drug safety attracted unprecedented mainstream attention. As new vaccines entered the market, and as a spectrum of different treatments was applied, the ability to quickly and efficiently capture accurate data, spot trends, draw robust conclusions about emerging safety issues, and act on them promptly became tangible - and expected by the public.
Pyrogens represent a broad family of molecules that, when present in parenteral drugs, may induce adverse reactions in humans, ranging from fever to septic shock. This is why pyrogenicity testing became mandatory for injectable products, initially only with the Rabbit Pyrogen Test (RPT). However, the European Pharmacopoeia (Ph. Eur.) has now effectively banned the RPT and revised 57 monographs to remove the reference to it.
The Standard Operating Procedures (SOPs) created by Artificial Intelligence (AI) using Microsoft CoPilot Software were compared to the Procedures provided in Previously Published Manuscripts to determine if AI assisted and improved the Procedures.
Awareness of the potential presence of nitrosamine compounds in foods and drugs has continued to evolve. The publication of regulatory guidance has strengthened risk assessment and mitigation actions in pharmaceutical companies. This article presents a multivariate analysis case study supporting initial diagnostics on key factors suspected to influence reaction dynamics in the formation of nitrosamines.
The rise of scourges, several infectious diseases, and a variety of diseases necessitate the development of new pharmacological innovations using activated nitrogen-based compounds. All living things have the pyrimidine component, which has several important
biological characteristics. This work outlines a straightforward, synthesized approach for creating heterocyclic components with several nitrogen-rich atoms acting as crucial components for creating
new diabetic medications.